生技產業已是目前的明星產業，政府正大力推展台灣生技產業發展，中央研究院
的基因體中心更是具有研究規模，政府為鼓勵產業發展更是在竹北設立生醫園區、及
在南港設立國家生技園區，也由於生技產業的領域相當廣泛，因此再生醫學產業成為
近年來大家最為熱烈討論的項目之一；尤其是 2012 年幹細胞研究獲得諾貝爾獎殊榮
肯定後，越來越多台灣幹細胞公司不僅儲存幹細胞，也開始從事幹細胞新藥的開發。
由於幹細胞新藥與一般新藥開發方式不同，幹細胞新藥是以幹細胞為主要原料，做成
細胞製劑進行植入性治療，所以開發方式和規格不同於一般藥物。幹細胞製劑的開發，
目前在台灣並沒有任何公司可以成為幹細胞新藥產業的標竿，同時也未有幹細胞新藥
在台灣被核准上市。因此，國璽公司發展出屬於自己的研發及營銷模式，希望能夠透
過集團所屬公司的資源整合，創造新藥以外的營業收入，使公司可以永續經營。所以
本研究使用質化法搭配量化分析方法，藉由分析國璽公司所屬的達文希診所的患者狀
況，來探討國璽公司發展新藥的可行性。本研究以國璽公司和達文希診所為研究對象，
採用文獻分析法探討幹細胞新藥目前的發展，並運用迴歸分析，針對客戶進行資料分
析，發現達文希診所的患者對類細胞治療的需求與意願。因此，本研究結果認為台灣
非常具有發展出幹細胞新藥的可行性。

The biotechnology industry currently is a star industry. The government is vigorously promoting the development of Taiwan’s biotechnology industry. The Genomics Center of the Academia Sinica has a research scale. The government has set up a biomedical park in Zhubei as well as a national biotechnology park in Nangang to encourage the industrial production. Because the field of biotechnology industry is quite wide, the regenerative medicine industry has been heatedly and broadly discussed in recent years, especially following the stem cell research who won the Nobel Prize in 2012. More and more Taiwan stem cell companies not only store stem cells, but also start to develop new stem cell drugs. The new stem cell drugs are developed differently from general new drugs. Stem cell new drugs use stem cells as the main raw material to make cell preparations for implantable treatment, so the development methods and specifications are different from general drugs. For the development of stem cell preparations, few companies in Taiwan have become the benchmark in the new stem cell drug industry, and few new stem cell drugs have been approved for marketing in Taiwan. Therefore, the company Gwoxihas developed its own R&D process and marketing model, hoping to create operating income other than new drugs through the integration of the resources of the group's companies, so that the company can operate sustainably. Therefore, this study uses qualitative methods and quantitative analysis methods to analyze the feasibility of developing new drugs for Gwoxi by analyzing the patient status of DMC Clinic, which belongs to Gwoxi. In this study, Gwoxiand DMCClinic were used as the research objects. The doctrinal analysis was used to explore the current development of new stem cell drugs. The regression analysis was used as the research method for analyzing the data for customers revealing that patients at the DMC Clinic needed and wanted cell-like therapies. Therefore, the results of this study suggest that Taiwan is very feasible to develop new stem cell drugs.

中文文獻
王玉祥，2000 年。「造血幹細胞移植的演進」。 台灣醫學 ，4 卷 2 期，177 - 186。
克里斯汀生(Clay M. Christensen)著，哈佛商業評論編譯，2016 年。 精讀克里斯汀生 。
台北：遠見天下文化出版股份有限公司。
周中林，2007 年。 台灣幹細胞產業經營策略 之研究 以個案公司為例 。碩士論文，國
立臺北大學國際財務金融碩士在職專班。
張明富，2003 年。 後基因體時代之生物技術 。教育部顧問室:生物技術科技教育改進
計畫。
莊明熙, 2016 年。 幹細胞新藥產業創新經營策略 。碩士論文，清華大學高階經營管理
碩士在職專班。
華聯快訊，2012 年。「誘導性多功能幹細胞與再生醫學」 。 新竹：華聯生物科技股份
有限公司 。
楊玉齡譯，2006 年。Ann B. Parson 著， 海神效應 。台北：張老師文化。
經濟部工業局，2013 年。 台灣生技產業的範圍 2015
生技產業白皮書 。台北：經濟部
工業局。
熊仲川，2011 年。「 簡介間質幹細胞的基礎研究與臨床運用」。 台灣醫界 ，54 卷 12 期，
29-34。
鄭信德，2014 年。「臺灣生技產業效益之分析」。 臺灣銀行季刊 ， 60 卷 3 期，71-95。
劉尚志，2001 年。「智慧財產權與產業競爭-產業競爭、科寄發展與法律規範之策略
思維」。 競爭政策通訊 ，5 卷 5 期，1-10。
劉岱良主編，2008 年。 喚醒生命力 — 幹細胞研究與再生醫學 。臺北：新學林出版股
份有限公司。

41
英文文獻
Aaker, D. A., 1989. “Managing Assets and Skills: The Key to Sustainable Competitive.
Advantage,” California Management Review, 31(2): 91–106.
Arojarvi, O., 2001. “How to Value Biotechnology Firms: A Study of Current Approaches
and Key Value Driver,” Master’s Thesis in Finance Theory, Helsinki School of
Economics and Business Administration.
Baker, Monya, 2007. “Adult Cells Reprogrammed to Pluripotency, without Tumors”. Nature
Reports Stem Cells. From: https://www.nature.com/articles/stemcells.2007.
Bang, O. Y., Kim, E. H., Cha, J. M., and G. J. Moon, 2016. “Adult Stem Cell Therapy for
Stroke: Challenges and Progress,” Journal of Stroke, 18(3): 256–266.
Barney, J.B., 1986. “Strategic Factor Markets: Expectations, Luck and Business Strategy”.
Management Science, 32(10): 1231–1241.
Barney, J.B., 1986. “Organizational Culture: Can It be a Source of Sustained Competitive
Advantage?” Academy of Management Review, 11(3): 656–665.
Betz, F., 2003. Managing Technological Innovation: Competitive Advantage from Change.
New Jersey: John Wiley & Sons.
Case: Oliver Brüstlev Greenpeace e.V.REFERENCE for a preliminary ruling under Article
267 TFEU from the Bundesgerichtshof (Germany), made by decision of 17 December
2009, received at the Court on 21 January 2010.
Fishman, M. C., and J. A. Porter, 2005. “Pharmaceuticals: A New Grammar for Drug
Discovery,” Nature, 437: 491−493.
Hofer, C. W., and D. Schendel, 1980. Strategy Formulation: Analytical Concepts. St.
Paul : West Publishing Company.
IMS., 2012. The Global Use of Medicines: Outlook Through 2016. IMS Institute for
Healthcare Informatics.
Mansfield, E., and S. Wagner, 1975. “Organizational and Strategic Factors Associated with

42
Probabilities of Success in Industrial R&D,” Journal of Business, 48(2):179-198.
Mason C. and P. Dunnill, 2008. “A Brief Definition of Regenerative Medicine,”
Regenerative Medicine, 3(1):1-5.
Murdick, R. G., Eckhouse, R. H., Moor, R.C., and T.W. Zimmerer, 1980. Business Policy:
A Framework for Analysis (3rd ed.), Columbus, OH: Grid Publishing.
Niosi, J., and T. G. Bas, 2001. “The Competencies of Regions–Canada’s Clusters in
Biotechnology,” Small Business Economics, 17(1-2):31-42.
Patrick Sullivan, 1996. “Focus Groups Confirm that MDs, Public Differ on Role of Private
Health Care.” Canadian Medical Association Journal, 154:1247-1249.
Perez, Carlota, 2001. “Technological Change and Opportunities for Development as a
Moving Target,” CEPAL Review, 75: 109-129.
Porter, M. E., 1980. Competitive Strategy: Techniques for Analyzing Industries and
Competitor. New York: The Free Press.
Porter, M.E., 1990. The Competitive Advantage of Nations. New York: Free Press,
MacMillan.
Rosenkopf, L., and M. Tushman,1992. “On the Organizational Determinants of
Technological Change: Towards a Sociology of Technological Evolution,” Research
in organizational behavior, 14: 311-347.
Takeuchi, Hirotaka and Ikujiro Nonaka, 1986. “The New Product Development Game,”
Harvard Business Review, 64(1):137-146.
Teece, David J., 1996. “Firm Organization, Industrial Structure, and Technological
Innovation,” Journal of Economic Behavior & Organization, 31(2): 193-224.
Till, J.E. and E. A. McCulloch, 1961. “A Direct Measurement of the Radiation Sensitivity of
Normal Mouse Bone Marrow Cells,” Radiation Research, 14: 213-222.
Wernerfelt, B., 1984. “The Resource-Based View of the Firm,” Strategic Management
Journal, 5(2):171–180.

43

網絡文獻 自由時報，2017 年。「日本京大 iPS 助教論文造假，諾貝爾獎得主道歉」。檢自
https://news.ltn.com.tw/news/world/breakingnews/2319802。
自由時報，2017 年,「前美國 FDA 官員陳紹琛：台灣發展生技法規太落伍」。檢自
https://ec.ltn.com.tw/article/paper/1090155。
江偉芬， 2013 年。「新藥開發技術之日韓前瞻趨勢分析」。科技產業資訊室。檢自
https:// iknow.stpi.narl.org.tw/post/Read.aspx?PostID=8834。
張品俞，2011年。「再生醫學及組織重組工程的前景與方向」。社團法人生技醫療產
業策進會。檢自 http://www.ibmi.org.tw/client/ReportDetail.php?REFDOCTYPID
=0kv7fkfs6uh20qiu&REFDOCID=0lnhtssxxtp17eln。
國璽幹細胞應用技術股份有限公司，2016年。「 幹細胞新藥GXHPC1-清肝淨」。檢自
http://www.gwoxi.com.tw/index.php/frontend/tmp_cell_drug/view?tmp_cell_drug_id
=5。
鄧哲明，2013年。「新藥的研發流程概論」，『科學月刊』。檢自
http://scimonth.blogspot.tw/2013/03/blog-post_6173.html。
Evaluate Pharm. (2015). “World Preview 2015, Outlook To 2020”,
https://info.evaluategroup.com/rs/607-YGS-364/images/wp15.pdf
Lund Stem Cell Center. (2003). “Sweetland Setup in January,2003”,
https://www.stemcellcenter.lu.se/research-school
NobelPrize.org. (2012).“The Nobel Prize in Physiology or Medicine 2012”,
https://www.nobelprize.org/prizes/medicine/2012/summary/